Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.83 |
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749287 | 0.93 | PRCP (0.72) | PRCPRBP4PROKR1SYKCNR1 | |
| SCHEMBL14686541 | 0.91 | PRCP (1.00) | PRCPRBP4SYKMAPK13MAPK12 | |
| SCHEMBL14749338 | 0.89 | PRCP (0.65) | PRCPSYKALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12183983 | 0.87 | PRCP (0.64) | PRCPSYKALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14749335 | 0.87 | PRCP (0.64) | PRCPPROKR1ALDH1A1KDM4E | |
| SCHEMBL14752561 | 0.86 | PRCP (0.62) | PRCPPROKR1SYKCNR1ALDH1A1 | |
| SCHEMBL14749328 | 0.86 | PRCP (0.61) | PRCPPROKR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14749365 | 0.85 | PRCP (0.60) | PRCPSYKCNR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14749329 | 0.84 | PRCP (0.59) | PRCPALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14749333 | 0.84 | PRCP (0.59) | PRCPALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| WO-2011146354-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885RBP4 354/4885PROKR1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.